ClinicalTrials.gg
CompletedNCT03156907SEVROPUpdated Nov 10, 2026

High Dosage Buprenorphine as a Drug Strategy Withdrawal Assistance of Analgesics Opioid

A Phase 2 interventional study of Buprenorphine in High Dosage Buprenorphine, sponsored by University Hospital, Clermont-Ferrand. Completed at 1 site in France. Open to participants aged 18 Years to 100 Years. Per ClinicalTrials.gov, last updated 2026-11-10.

Sponsored by University Hospital, Clermont-Ferrand · Phase 2, Interventional, and Treatment

How we know

Updated Nov 10, 2026Now CompletedResults publication added+3 moreGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
22
Allocation
Not applicable
Ages
18 Years to 100 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 22 studies testing buprenorphine in Chronic Pain — 1 open to participants now, 1 under way, none of them phase 3. Buprenorphine · Chronic Pain.

Enrollment
18th of 22
22 · median 207
Started
2017
the only one that year
Phase 2
2 of 22
none open now
Registered
18th of 22
by date

Among the 22 studies testing buprenorphine in Chronic Pain, this one is the 18th largest by enrollment, is the only one that started in 2017, is one of 2 in phase 2, and was the 18th registered.

Chronic Pain

3,230 studies on the registry are indexed under Chronic Pain; 728 are open to participants now.

Browse Chronic Pain studies →

Open to participants now

1 of the 22 studies testing buprenorphine in Chronic Pain is open now, in 1 country. Recruiting first, the newest first:

By country, each count listing its studies:

About buprenorphine

Buprenorphine: first FDA approval 1981 (BUPRENEX), first EMA approval 2006. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 486 Chronic Pain studies recruiting now, 239 (49%) set no upper age limit and 173 (36%) stop at 75 or younger; 43 take children under 18; 64 take healthy volunteers.

This study: 18 Years to 100 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 22 studies testing buprenorphine in Chronic Pain, or all of them as a file.
02

Study summary

The prevalence of analgesics opioids addiction in chronic pain patient is very difficult to know. Many studies indicated that the prevalence of addiction varied from 0% up to 50% in chronic non cancer pain patients, and from 0% up to 7.7% in cancer pain patients. Analgesics opioids use have increasingly been increased in chronic pain for 20 years. However, a long use, at least 3 months in this type of pain has not proved a large efficiency and we have noticed a habituation, tolerance and withdrawal when treatment was decreased or stopped. In current practice, patients with chronic pain, often keep their analgesics opioids despite the absence of pain relief and benefits in quality of life.

Nowadays, no withdrawal strategy is the reference in chronic non-cancer pain patients with physical opioid dependence. The most common clinical strategy is progressive decrease of analgesic opioid. But this strategy is often a failure in these patients (no data are available in literature).

It's necessary to make a prospective pilot study to assess benefits from this practice.

The primary objective of this study is to assess a new ambulatory withdrawal strategy, consisting of a temporary opioid rotation with buprenorphine in CNCP patients suffering from physical withdrawal symptoms and who have failed a conventional strategy of progressive withdrawal from their opioid analgesic treatment.

Read the detailed description

This study is designed as a type 2 multicenter clinical trial combining 3 Pain Clinics.

Patients were consecutively recruited from the active file of 3 Pain Clinics in France (Clermont-Ferrand, Vichy and le Puy-en-Velay). Patients meeting all inclusion criteria were enrolled after receiving oral and written information about the study and after obtaining written informed consent.

At baseline, they completed 5 questionnaires including: Brief Pain Inventory (BPI), Hospital Anxiety and Depression scale (HAD), Leeds sleep Evaluation Questionnaire (LSEQ), Short version of Short Form 36 Health Survey (SF 12), Clinical Opioid Withdrawal Scale (COWS) and underwent 2 tests with algometer and pupillometer. After inclusion, all patients started an opioid tapering-off protocol (Figure 1, Step 1) according to a standardized scheme of opioid gradual decrease defined by 3 medical experts in addictology, pain management and pharmacology.

Step 1 (from inclusion to 3 months): Patients will start to taper off their opioid dose according to a specific schedule. They will be seen by a physician on a monthly basis and contacted by phone 48-72h after each decrease in opioid dosage to detect withdrawal symptoms using the COWS specific scale. After 3 months, all patients who fail the opioid tapering-off protocol will be included in a non-responder group, while the others who succeed the withdrawal protocol will be included in a responder group:

  • A responder will be defined by strict adherence to the schedule leading to a 50% reduction in the initial daily dose of opioid after 3 months. In this case, patients will continue with step 1 and decrease their opioid dose according to the same withdrawal protocol. They will be seen by a physician on a monthly basis and contacted by phone 48-72h after each stage of opioid dose reduction, until the opioid treatment is completely discontinued after 6 months of the withdrawal protocol. At 6 months, patients will fill out the same questionnaires and perform the same tests as at the baseline visit. Finally, after 9 months, patients will be contacted by phone to check that withdrawal is being maintained and to collect data on ongoing analgesic treatment.
  • A non-responder will be defined as a failure of the withdrawal protocol, by non-compliance with the schedule, leading to a 50% reduction in the initial daily dose of opioid treatment after 3 months or when tapering off fails, leading the patient to re-increase the opioid dose. Thus, these patients will proceed to step 2 and start temporary rotation with buprenorphine.

Step 2:

  • From D0 to D0+28 days - buprenorphine treatment/stabilization Buprenorphine will be administered initially (D0) for 28 days at a dose of 4 mg/day (possible adjustment of ±2mg/day with the possibility to increase the dose up to 8 mg/day during the first 24-48 hours, depending on the severity of withdrawal symptoms or patient tolerance). Questionnaires (BPI, HADS, LSEQ, SF-12, COWS) and tests (algometer and pupillometer) will be completed at D0, and the physician will assess the efficacy and safety of buprenorphine by phone call at D0 + 24h/48 h and at D0 + 7 days.
  • From D0 + 28 days to D0 + 9th month after rotation by buprenorphine The buprenorphine treatment will be tapered off in 1 mg steps every 28 days until the complete cessation of buprenorphine after 9 months of withdrawal. Patients will be seen by a physician every 28 days and will be contacted by phone 48-72h after each decrease in the buprenorphine dose. The COWS questionnaires and a pain assessment (11-point NRS) will be completed at each medical consultation.
  • D0 + 9th month A urine opioid test (primary outcome) will be performed to validate the total opioid withdrawal (including buprenorphine). Patients will complete different questionnaires (BPI, HADS, LSEQ, SF 12, COWS) and perform different tests (algometer and pupillometer).
  • Follow-up phone call at 12 months The patients will be contacted by phone to check on their continued withdrawal and ongoing analgesic treatment.
03

Conditions studied

  • High Dosage Buprenorphine

Keywords

  • High dosage Buprenorphine (HDB)
  • Chronic pain
  • Analgesics opioids
  • Withdrawal symptoms
04

Who can participate

Ages eligible
18 Years to 100 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Patients >= 18 years,
  • patients with CNCP who have been treated for more than 6 months with a single opioid analgesic (weak or strong; long acting and/or immediate release),
  • Patients will be required to have an indication to stop or reduce opioid therapy (i.e. unfounded indication, tolerance, ineffectiveness, and/or adverse effects), and/or have physical withdrawal symptoms between opioid administrations (Clinical Opioid Withdrawal Scale (COWS) assessment),
  • Patients must have given their comprehensive and be affiliated with the French social security system.

Exclusion criteria

Exclusion Criteria:

  • not have an opioid use disorder with craving (assessment by investigator according to the (DSM-5)) or misuse (assessment by the Prescription Opioid Misuse Index (POMI)[28]) related to opioid use,
  • ongoing treatment with ketamine,
  • chronic cancer pain,
  • to buprenorphine ( to an active substance or its , severe hepatic and/or respiratory dysfunction, alcohol use disorder or delirium tremens),
  • alcohol use disorder,
  • pregnant or breastfeeding,
  • involved in any other interventional trial, or be subject to legal protection.
Terms in these criteria, in plain language(5)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

DSM diagnostic criteria

The American Psychiatric Association’s manual of mental health diagnoses. DSM-5 (2013, revised as DSM-5-TR in 2022) replaced DSM-IV, and some studies still name the older edition. “Meets DSM criteria for …” means diagnosed by that edition’s diagnostic criteria, usually by a clinician in an interview.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Excipients

The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
22 participants (actual)

Study arms

  • Experimental
    Chronic pain patients

    The primary objective of this study is to assess the success rate at 6 months of opioid temporary rotation by High Dosage Buprenorphine (HDB) taper dose in chronic non cancer pain patients (CNCP) with physical withdrawal symptoms making opioid withdrawal impossible.

    Drug: Buprenorphine

Interventions

  • HDB is started (J0) at the dosage of 4 mg/ day (with a possible adjustment ± 2 mg at 24h, depending on the patient withdrawal symptoms intensity or tolerance).

06

What researchers measure

Primary outcomes

  1. Absence of opioid in urine test after rotation by HDB

    Validating total opioid withdrawal (including HDB)

    Time frame: Month 6

Secondary outcomes

  1. Rate of opioid tapering-off protocol success by decrease of 50% of initial posology

    Time frame: Month 3

  2. Rate of opioid tapering-off protocol success by total taper opioid withdrawal

    Time frame: Month 6

  3. The pain will be assessed by the questionnaire Brief pain Inventory (BPI)

    Time frame: Day 1, Month 1, Month 6

  4. The quality of life will be assessed by questionnaire SF12 (Short version of Short Form 36 Health Survey)

    Time frame: Day 1, Month 1, Month 6

  5. The anxiety and depression will be assessed by questionnaire HAD (Hospital anxiety and depression scale)

    Time frame: Day 1, Month 1, Month 6

  6. The sleep will be assessed by questionnaire LSEQ (Leeds sleep evaluation questionnaire)

    Time frame: Day 1, Month 1, Month 6

  7. Evaluation of the correlation between pupillary dilation (pupillometer) and pain (NRS 0-10).

    Time frame: Day 1, Month 1, Month 6

  8. Evaluation of pain intensity (NRS 0-10) by the pressure algometry measurement.

    Time frame: Day 1, Month 1, Month 6

07

Study locations

1 site
  • CHU Clermont-Ferrand
    Clermont-Ferrand, Auvergne 63003, France
08

References and documents

Publications

  • Bertin C, Kerckhove N, Ferrer F, Pereira B, Duale C, Richard D, Authier N, Delage N. Buprenorphine Substitution as a Tapering Strategy for Opioid Discontinuation in Patients with Chronic Pain: A Nonrandomized and Proof of Concept Study. Pain Ther. 2025 Dec;14(6):1783-1795. doi: 10.1007/s40122-025-00781-z. Epub 2025 Oct 3. PubMed 41042438 ↗
09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedDate before it movedWhere the date was before it movedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Sep 2017 to primary completion in Nov 2022, 62 months.

Of 47 non-industry phase 2 interventional studies under Chronic Pain, half reached primary completion within 42 months of starting (the median), counting those still running; a quarter within 25 and three quarters within 52. This study's 62 months is above that.

Counting every sponsor, half of 60 studies reached it within 37 months; a quarter within 21 and three quarters within 52.

Since we started tracking on Sep 25, 2026, the dates moved once, on Nov 10, 2026: primary completion Dec 2024 → Nov 2022 and completion Mar 2025 → Nov 2023.

Earlier changes are on the record history on ClinicalTrials.gov ↗

How these figures are worked out, and which studies are left out of them.

Registered
May 5, 2017
First posted
May 17, 2017
StartActual
Sep 15, 2017
Primary completionActual
Nov 30, 2022was Dec 2024
CompletionActual
Nov 30, 2023was Mar 2025
Last update
Nov 10, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Status
Status unknown→Completed
changed Nov 10, 2026
Primary completion
Dec 2024→Nov 30, 2022 (actual)
Nov 10, 2026
Study completion
Mar 2025→Nov 30, 2023 (actual)
Nov 10, 2026
Enrollment
60 (estimated)→22 (actual)
Nov 10, 2026
Publications
Results publication added: Bertin C, Kerckhove N, Ferrer F, Pereira B, Duale C, Richard D, Authier N, Delage N. Buprenorphine Substitution as a Tapering Strategy for Opioid Discontinuati… PubMed 41042438 ↗
Nov 10, 2026
Show all 1 update
  1. Nov 10, 2026
    Status unknown→Completed
    Publications Results publication added: Bertin C, Kerckhove N, Ferrer F, Pereira B, Duale C, Richard D, Authier N, Delage N. Buprenorphine Substitution as a Tapering Strategy for Opioid Discontinuati… PubMed 41042438 ↗
    Primary completion Dec 2024→Nov 30, 2022 (now actual)
    Study completion Mar 2025→Nov 30, 2023 (now actual)
    Enrollment 60 (estimated)→22 (actual)
    + 3 other changes: identifiers, verification date and site details

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT03156907
Responsible party
Sponsor
First posted
May 17, 2017
Start date
Sep 15, 2017
Primary completion
Nov 30, 2022
Completion
Nov 30, 2023
Last update
Nov 10, 2026

Oversight

FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Dec 2023. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Buprenorphine

Start the discussion